alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 32.1**

 

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER ANDCHIEF FINANCIAL OFFICERPURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

I, Carlton H.Baab, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Reportof Raining Data Corporation on Form 10-QSB for the quarterly period endedDecember 31, 2003 fully complies with the requirements of Section 13(a) or15(d) of the Securities Exchange Act of 1934 and that information contained insuch Form 10-QSB fairly presents in all material respects the financialcondition and results of operations of Raining Data Corporation.

 
|   | By:    | /s/ Carlton  H. Baab                   |   |
|--------|--------|----------------------------------------|--------|
|   | Name:  | Carlton H.  Baab                       |
|   | Title: | President  and Chief Executive Officer |

 

I, Brian C.Bezdek, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuantto Section 906 of the Sarbanes-Oxley Act of 2002, that the QuarterlyReport of Raining Data Corporation on Form 10-QSB for the quarterly periodended December 31, 2003 fully complies with the requirements ofSection 13(a) or 15(d) of the Securities Exchange Act of 1934 and thatinformation contained in such Form 10-QSB fairly presents in all materialrespects the financial condition and results of operations of Raining DataCorporation.

 
|   | By:    | /s/ Brian C.  Bezdek     |   |
|--------|--------|--------------------------|--------|
|   | Name:  | Brian C.  Bezdek         |
|   | Title: | Chief  Financial Officer |

 

----
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Child Health and Human Development Initial Review Group; Obstetrics and Maternal-Fetal Biology Subcommittee.                    

*Date:*                         June 15, 2009.                    

*Time:*                         9 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878.                    

*Contact Person:*                         Gopal M. Bhatnagar, PhD, Scientific Review Administrator, National Institute of Child Health and Human Development, National Institutes of Health, 6100 Executive Boulevard, Rm 5B01, Rockville, MD 20852, (301) 435-6889,                         *bhatnagg@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: May 15, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-12197 Filed 5-26-09; 8:45 am]

BILLING CODE 4140-01-P
EXHIBIT 32.1

SECTION 906 CERTIFICATION - CEO

In connection with the Annual Report of Plains
Exploration & Production Company (the Company) on Form 10-K for the period ending December 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, James C. Flores,
Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

To the best of my knowledge, after reasonable investigation:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------

Dated: February 23, 2012



/s/ James C. FloresJames C. FloresChief Executive Officer


The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 and is not being filed as part of the Report or as a separate disclosure document.

A signed original of this written statement required
by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the
Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
#### The People of the State of New York, Respondent, v Joseph Hightower, Appellant.

Submitted January 3, 2011;

decided January 6, 2011

Motion for assignment of counsel granted and Steven Banks, Esq., the Legal Aid Society, 199 Water Street, New York, NY 10038 assigned as counsel to the appellant on the appeal herein.
<PAGE>   1
                                                                  EXHIBIT 10.17


              [CELEBRITY EXPORTS INTERNATIONAL LIMITED LETTERHEAD]



To:  The Manager                                                  19 May, 1997
The Hongkong and Shanghai Banking Corporation Limited
673 Nathan Road,
Kowloon



Dear Sirs,

RE: BANKING FACILITIES

In consideration of your agreeing to grant credit facilities and other
financial accommodation to us or at our request upon and subject to such terms
and conditions as you shall from time to time think fit, we, Celebrity Exports
International Limited, hereby irrevocably and unconditionally covenant and
undertake with you that our net worth maintaining for not less than HKD50
Million for all times.





Yours faithfully,


For and on behalf of 
CELEBRITY EXPORTS INTERNATIONALLY LTD.


/s/ ROBERT H. PATTERSON, JR.
---------------------------------------
Authorized Signature
<PAGE>   1
                                                                    EXHIBIT 22.1


                           SUBSIDIARIES OF THE COMPANY



Clientele Software, Inc.

Cypher Business Systems Limited

Platinum (Colorado) Inc.  (FKA Frx Software, Inc.).

Platinum Software (Aust.) Pty., Limited

Platinum Software BVI, Ltd.

Platinum Software Canada, Ltd.

Slatershelfco 173 Limited

Platinum Software Foreign Sales Corporation, Inc.

Platinum Software (Holdings)Limited

Platinum Software (Ireland) Limited

Platinum Software North Asia, Ltd.

Platinum Software (NZ) Limited

Platinum Software (UK) Limited

Platinum (Asia) Pte Ltd.

Platinum Software Corporation Sdn. Bhd.
#### ELECTRIC RENOVATOR MFG. CO. v. VACUUM CLEANER CO. et al.

(Circuit Court, W. D. Pennsylvania.

October 7, 1911.)

No. 96.

On rehearing.

For former opinion, see 189 Fed. 754.

ORR, District Judge.

A rehearing was had this 9th day of October, 1911, upon the motion on the part of the defendant to dissolve and vacate the preliminary injunction heretofore granted. The argument on the part of the defendant indicated that it thought the injunction was originally issued by the court upon the theory that the defendant had no right to assert title to its patent or to charge infringement on the part of those using the patent. This was not the intent of the injunction, but it was to restrain the defendant from making threats or warnings against users when the defendant had not complied with the plaintiff’s request that a proceeding to test the validity of the patent should be instituted. The notices sent out contained such Inaguage as the following:

> “You may suggest that your contract with the manufacturers protects you from any ultimate damages that we might claim. We only ask you to look into the standing of the people from whom you are buying. We think you will find that 90 per cent, of all of the unlicensed manufacturers are not strong enough to afford any real protection.”

It appears that recently the defendant has eliminated that language from a circular letter which had been prepared and which it was accustomed to send out. The court believes that the injunction, as modified, in accordance with the opinion heretofore filed upon this question, should stand.
No. 277.

#### Dinan et al. *v.*First National Bank.

February 2, 1942.

Certiorari, 314 U. S. 593, to the Circuit *825Court of Appeals for the Sixth Circuit. Dismissed on motion of counsel for the petitioners.

*Mr. John B. Rood*for petitioners. *Messrs. Robert S. Marx*and *George P. Barse*for respondent.
<TABLE> <S> <C>


<ARTICLE>                     5
<CIK>                         0000892038
<NAME>                        TELEPAD CORPORATION

<S>                             <C>
<PERIOD-TYPE>                      12-MOS
<FISCAL-YEAR-END>              DEC-31-1998
<PERIOD-START>                 JAN-01-1997
<PERIOD-END>                   DEC-31-1997
<CASH>                          1,588,790
<SECURITIES>                            0
<RECEIVABLES>                   1,507,231
<ALLOWANCES>                       88,000
<INVENTORY>                     1,174,507
<CURRENT-ASSETS>                5,652,945
<PP&E>                            871,518
<DEPRECIATION>                   (489,895)
<TOTAL-ASSETS>                  6,258,159
<CURRENT-LIABILITIES>           2,323,281
<BONDS>                                 0
<PREFERRED-MANDATORY>                   0
<PREFERRED>                             0
<COMMON>                        3,934,878
<OTHER-SE>                              0
<TOTAL-LIABILITY-AND-EQUITY>    6,258,159
<SALES>                         3,348,398
<TOTAL-REVENUES>                3,592,577
<CGS>                           4,282,929
<TOTAL-COSTS>                   5,099,724
<OTHER-EXPENSES>                5,349,472
<LOSS-PROVISION>                        0
<INTEREST-EXPENSE>                   (214)
<INCOME-PRETAX>                (6,557,713)
<INCOME-TAX>                            0
<INCOME-CONTINUING>            (6,557,713)
<DISCONTINUED>                          0
<EXTRAORDINARY>                         0
<CHANGES>                               0
<NET-INCOME>                   (6,557,713)
<EPS-PRIMARY>                       (0.56)
<EPS-DILUTED>                           0



</TABLE>
#### State v. Bullock

Case below: 178 N.C. App. 460

No. 448P06

Def’s PDR Under N.C.G.S. § 7A-31 (COA05-43)

Denied 01/25/07
## Breadcrumb

-  Home 
-  Research 
-  Intramural Research 

# Genomics and Computational Biology Core

**Robert Morell, Ph.D., Director**

## Mission

The NIDCD Genomics and Computational Biology Core (GCBC) provides support for cutting edge high-throughput sequencing technologies to NIDCD and National Institute of Dental and Craniofacial Research (NIDCR) investigators on a collaborative basis. Our services include library preparation of investigator-supplied RNA or DNA samples, sequencing data generation, bioinformatic analyses, and publication-ready figure preparation. Intramural NIDCD and NIDCR investigators are charged for reagent costs of library preparation and sequencing only. The GCBC also archives the data and assists investigators in uploading the necessary data files to a suitable public repository, in compliance with NIH genomic data sharing policy.

Current projects in the GCBC include:
                - Whole exome and whole genome sequencing
                - Tissue-level RNA-seq
                - Single-cell and single-nuclei RNA-seq
                - Epigenomics (ChIP-seq, ATAC-seq, etc.)
                - Custom projects

Sequencing platforms:
                - Illumina HiSeq1500
                - Illumina NextSeq500
                - Illumina MiSeq
                - Oxford Nanopore MinIon
                - PacBio Sequel II

## Lab Personnel

                - Robert Morell, Ph.D.  Staff Scientist  +1 301 402 4249  (Send e-mail)
                - Begum Choudhury  Biologist  +1 301 443 2401  (Send e-mail)

            - Erich Boger, Ph.D.  Contractor, Biologist  +1 301 402 7853  (Send e-mail )
            - Kerianne Richards, M.S.  Contractor, Bioinformatics  +1 301 443 2401  (Send e-mail )
            - Daniel Martin Izquierdo, Ph.D.  (NIDCR)  +1 301 402 7535 (Send e-mail)
            - Zheng Wei, Ph.D.  (NIDCR)  +1 301 827 6949 (Send e-mail)

Left to right: Zheng Wei, Keri Richards, Dani Martin Izquierdo, Erich Boger, Rob Morell.

June 4, 2019

## NIDCD Research in the News

                - Study charts developmental map of inner ear sound sensor in mice
                - Novel drug therapy partially restores hearing in mice
                - Researchers find molecular similarities among head and neck, lung, and bladder cancers
IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 22

- 0041 STATE OF MONTANA,

Plaintiff and Appellee,

v. JAMES MICHAEL PARKER,

Defendant and Appellant.

**ORDER** Upon consideration of Appellant’s motion for extension of time to produce transcripts on appeal, and good cause appearing, IT IS HEREBY ORDERED that Court Reporter Wendy D. Fiske is granted an extension of time to and including June 15 , 2022 , within which to prepare, file, and serve the transcripts requested on appeal. The Clerk shall serve a copy of this Order upon the district court and the court reporter.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

April 21 2022

04/21/2022

Case Number: DA 22-0041
II 

109TH CONGRESS 

1ST SESSION S. 893 

To make technical corrections in the Anabolic Steroid Control Act of 2004. 

IN THE SENATE OF THE UNITED STATES 

APRIL 25, 2005 

Mr. BIDEN introduced the following bill; which was read twice, considered, 

read the third time, and passed 

A BILL 

To make technical corrections in the Anabolic Steroid Control 

Act of 2004. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. TECHNICAL CORRECTIONS. 

4 Section 102(41)(A) of the Controlled Substances Act 

5 (21 U.S.C. 802(41)(A)), as amended by the Anabolic Ster6 oid Control Act of 2004 (Public law 108-358), is amended 

7 by— 

8 (1) striking clause (xvii) and inserting the fol9 lowing: 

10 ‘‘(xvii) 13β-ethyl-17β-hydroxygon-4-en-3-one;’’; 

11 and 
2 

•S 893 CPS 

1 (2) striking clause (xliv) and inserting the fol2 lowing: 

3 ‘‘(xliv) stanozolol (17α-methyl-17β-hydroxy4 [5α]-androst-2-eno[3,2-c]-pyrazole);’’. 

Æ
<PAGE>   1

                                                                    EXHIBIT 21.1

                           SUBSIDIARIES OF THE COMPANY

<TABLE>
<CAPTION>
                Name                                        Jurisdiction of Incorporation
------------------------------------------          -------------------------------------------
<S>                                                 <C>
Cypher Business Systems, Limited                    United Kingdom
Epicor Software (Aust.) Pty., Ltd.                  Australia
Epicor Software BVI, Ltd.                           British Virgin Islands
Epicor Software Canada, Ltd.                        Canada
Slatershelfco 173 Limited                           United Kingdom
Epicor Software (Holdings) Limited                  Ireland
Epicor Software (Ireland) Limited                   Ireland
Epicor Software (North Asia) Limited                Hong Kong
Epicor Software (NZ) Limited                        New Zealand
Epicor Software (UK) Limited                        United Kingdom
Epicor Software Asia PTE, Ltd.                      Singapore
DataWorks International Export Corporation          Barbados
Epicor Nederland B.V.                               Netherlands
Epicor Nordic A.B.                                  Sweden
Epicor France S.A.                                  France
Epicor Software (Argentina) S.A.                    Argentina
Evosoft (Epicor) Software GMBH                      Germany
</TABLE>
#### Angelica Racines, Respondent, v Jerome Lebowitz et al., Appellants.

[963 NYS2d 348]

—In an action to recover damages for personal injuries, the defendants appeal from an order of the Supreme Court, Queens County (McDonald, J), dated March 13, 2012, which denied their motion for summary judgment dismissing the complaint.

Ordered that the order is reversed, on the law, with costs, and the defendants’ motion for summary judgment dismissing the complaint is granted.

On the afternoon of August 9, 2009, the plaintiff allegedly tripped and fell near the entrance door of an automobile dealership owned by the defendants.

“Although proximate cause can be established in the absence of direct evidence of causation [and] . . . may be inferred from the facts and circumstances underlying the injury, mere speculation as to the cause of a fall, where there can be many causes, is fatal to a cause of action” *{Manning v 6638 18th Ave. Realty Corp.,*28 AD3d 434, 435 [2006] [internal quotation marks omitted]; *see Bolde v Borgata Hotel Casino & Spa,*70 AD3d 617, 618 *935[2010]; *Louman v Town of Greenburgh,*60 AD3d 915, 916 [2009]). Here, the defendants met their burden of establishing their prima facie entitlement to judgment as a matter of law by-demonstrating that the plaintiff was unable to identify the cause of her accident without engaging in speculation *(see Bolde v Borgata Hotel Casino & Spa,*70 AD3d at 618; *Louman v Town of Greenburgh,*60 AD3d at 916; *Manning v 6638 18th Ave. Realty Corp.,*28 AD3d at 435). In opposition, the plaintiff failed to raise a triable issue of fact *(see Bolde v Borgata Hotel Casino & Spa,*70 AD3d at 618; *Louman v Town of Greenburgh,*60 AD3d at 916; *Manning v 6638 18th Ave. Realty Corp.,*28 AD3d at 435).

Accordingly, the Supreme Court should have granted the defendants’ motion for summary judgment dismissing the complaint.

Rivera, J.E, Angiolillo, Chambers and Roman, JJ, concur.
<!DOCTYPE html>
<html>
<head>
    <meta name="viewport" content="width=device-width" />
    <meta name="robots" content="noindex">
    <title>Symptoms & Causes of Irritable Bowel Syndrome - NIDDK</title>
    
<meta name="VIcurrentDateTime" content="638491922970065864" />
<meta name="VirtualFolder" content="/" />
<script type="text/javascript" src="/layouts/system/VisitorIdentification.js"></script>

</head>
<body>
    <div></div>
</body>
</html>
<PAGE>
                                                                    EXHIBIT 23.1

               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

    We consent to the incorporation by reference in the Registration Statements
on Form S-3 (Nos. 333-102988, 333-85160, 333-61866, 333-25661, 333-32159,
333-23085, 333-17501, 333-03507 and 33-107755) and the Registration Statements
Form S-8 (Nos. 333-30558, 333-46990, 333-81243, 333-105694 and 333-105693),
pertaining to the 1992 Stock Option Plan, the 1993 Non-Employee Directors'
Equity Incentive Plan and the 2000 Employee Stock Purchase Plan of Questcor
Pharmaceuticals, Inc. of our report dated February 12, 2004, with respect to the
financial statements and schedules of Questcor Pharmaceuticals, Inc. included in
this Annual Report (Form 10-K) for the year ended December 31, 2003.

                                                /s/ Ernst & Young LLP


Palo Alto, California
March 29, 2004
EXHIBIT 32.1





CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report of Columbia Laboratories, Inc. (the “Company”) on Form 10-Q/A for the period ended September 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frank C. Condella, Jr., President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:





(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.








/s/ Frank C. Condella, Jr.


Frank C. Condella, Jr.


President and Chief Executive Officer


December 28, 2010
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from September
25, 2000 Form 10Q and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                         DEC-25-2000
<PERIOD-START>                            DEC-28-1999
<PERIOD-END>                              SEP-25-2000
<CASH>                                            347
<SECURITIES>                                        0
<RECEIVABLES>                                   2,278
<ALLOWANCES>                                        0
<INVENTORY>                                     2,145
<CURRENT-ASSETS>                                6,184
<PP&E>                                        107,400
<DEPRECIATION>                                 39,220
<TOTAL-ASSETS>                                 98,398
<CURRENT-LIABILITIES>                          21,565
<BONDS>                                             0
<PREFERRED-MANDATORY>                               0
<PREFERRED>                                         0
<COMMON>                                          118
<OTHER-SE>                                     50,862
<TOTAL-LIABILITY-AND-EQUITY>                   98,398
<SALES>                                       105,751
<TOTAL-REVENUES>                              105,751
<CGS>                                          34,828
<TOTAL-COSTS>                                  65,237
<OTHER-EXPENSES>                               23,731
<LOSS-PROVISION>                                    0
<INTEREST-EXPENSE>                              2,011
<INCOME-PRETAX>                               (5,407)
<INCOME-TAX>                                        0
<INCOME-CONTINUING>                           (5,407)
<DISCONTINUED>                                      0
<EXTRAORDINARY>                                     0
<CHANGES>                                           0
<NET-INCOME>                                  (5,407)
<EPS-BASIC>                                     (.46)
<EPS-DILUTED>                                   (.46)


</TABLE>